Tumor Biology

, Volume 36, Issue 8, pp 6551–6558 | Cite as

Co-expression of β-arrestin1 and NF-кB is associated with cancer progression and poor prognosis in lung adenocarcinoma

  • Jianyu Yu
  • Liguang Wang
  • Tiehong Zhang
  • Hongchang Shen
  • Wei Dong
  • Yang Ni
  • Jiajun Du
Research Article

Abstract

β-arrestin1 and NF-κB have been demonstrated to be associated with tumorigenesis, tumor progression, and metastasis. Thus far, there is nevertheless little study about these two molecules in lung adenocarcinoma. The aim of this study was to investigate the correlation between β-arrestin1 and NF-κB expression and the clinicopathological characteristics in lung adenocarcinoma. A total of 115 surgically resected lung adenocarcinoma patients were recruited for the study. Expression of β-arrestin1 and p65 were detected by immunohistochemistry (IHC) in lung adenocarcinoma tissue samples. Nuclear expression of β-arrestin1 and p65 were observed in 39.1 % (45/115) and 46.1 % (53/115) cases of lung adenocarcinoma, respectively. And high expression of β-arrestin1 had negative prognostic impact for overall survival (OS) and disease-free survival (DFS) (p = 0.034 and p = 0.033). In addition, overexpression of p65 indicated a significantly poor OS and DFS than those of lower-expression (p = 0.038 and p = 0.041). Furthermore, co-expression of nuclear β-arrestin1 and p65 correlated with poorer OS and DFS in lung adenocarcinoma patients. Multivariate analysis using the Cox regression model confirmed that co-expression of nuclear β-arrestin1 and p65 was an independent prognostic factor for tumor progression (p = 0.008). In conclusion, these data indicated that co-expression of nuclear β-arrestin1 and p65 was a novel predictor for worse prognosis in patients with lung adenocarcinoma.

Keywords

β-arrestin1 NF-κB p65 Lung adenocarcinoma Prognosis 

Notes

Acknowledgments

This research was supported (in part) by the Shandong Provincial Natural Science Foundation of China (ZR2013HZ001) and National Natural Science Foundation of China (81301728).

Conflict of interest

None

References

  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: Cancer J Clin. 2011;61:69–90.Google Scholar
  2. 2.
    Buchanan FG, DuBois RN. Emerging roles of beta-arrestins. Cell Cycle. 2006;5:2060–3.CrossRefPubMedGoogle Scholar
  3. 3.
    Kang J, Shi Y, Xiang B, Qu B, Su W, Zhu M, et al. A nuclear function of beta-arrestin1 in GPCR signaling: regulation of histone acetylation and gene transcription. Cell. 2005;123:833–47.CrossRefPubMedGoogle Scholar
  4. 4.
    Scott MG, Le Rouzic E, Perianin A, Pierotti V, Enslen H, Benichou S, et al. Differential nucleocytoplasmic shuttling of beta-arrestins. Characterization of a leucine-rich nuclear export signal in beta-arrestin2. J Biol Chem. 2002;277:37693–701.CrossRefPubMedGoogle Scholar
  5. 5.
    Wang P, Wu Y, Ge X, Ma L, Pei G. Subcellular localization of beta-arrestins is determined by their intact N domain and the nuclear export signal at the C terminus. J Biol Chem. 2003;278:11648–53.CrossRefPubMedGoogle Scholar
  6. 6.
    Xiao K, McClatchy DB, Shukla AK, Zhao Y, Chen M, Shenoy SK, et al. Functional specialization of beta-arrestin interactions revealed by proteomic analysis. Proc Natl Acad Sci U S A. 2007;104:12011–6.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Ma L, Pei G. Beta-arrestin signaling and regulation of transcription. J Cell Sci. 2007;120:213–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Parathath SR, Mainwaring LA, Fernandez LA, Guldal CG, Nahle Z, Kenney AM. Beta-arrestin-1 links mitogenic sonic hedgehog signaling to the cell cycle exit machinery in neural precursors. Cell Cycle. 2010;9:4013–24.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Yue R, Kang J, Zhao C, Hu W, Tang Y, Liu X, et al. Beta-arrestin1 regulates zebrafish hematopoiesis through binding to YY1 and relieving polycomb group repression. Cell. 2009;139:535–46.CrossRefPubMedGoogle Scholar
  10. 10.
    Buchanan FG, Gorden DL, Matta P, Shi Q, Matrisian LM, DuBois RN. Role of beta-arrestin 1 in the metastatic progression of colorectal cancer. Proc Natl Acad Sci U S A. 2006;103:1492–7.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Shenoy SK, Han S, Zhao YL, Hara MR, Oliver T, Cao Y, et al. Beta-arrestin1 mediates metastatic growth of breast cancer cells by facilitating HIF-1-dependent VEGF expression. Oncogene. 2012;31:282–92.CrossRefPubMedGoogle Scholar
  12. 12.
    Zecchini V, Madhu B, Russell R, Pertega-Gomes N, Warren A, Gaude E, et al. Nuclear ARRB1 induces pseudohypoxia and cellular metabolism reprogramming in prostate cancer. EMBO J. 2014;33:1365–82.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Dasgupta P, Rizwani W, Pillai S, Davis R, Banerjee S, Hug K, et al. ARRB1-mediated regulation of E2F target genes in nicotine-induced growth of lung tumors. J Natl Cancer Inst. 2011;103:317–33.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Witherow DS, Garrison TR, Miller WE, Lefkowitz RJ. Beta-arrestin inhibits NF-kappa B activity by means of its interaction with the NF-kappa B inhibitor I kappa B alpha. Proc Natl Acad Sci U S A. 2004;101:8603–7.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Aggarwal BB. Nuclear factor-kappaB: the enemy within. Cancer Cell. 2004;6:203–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Hoffmann A, Levchenko A, Scott ML, Baltimore D. The I kappa B-NF-kappa B signaling module: temporal control and selective gene activation. Science. 2002;298:1241–5.CrossRefPubMedGoogle Scholar
  17. 17.
    Ghosh S, May MJ, Kopp EB. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol. 1998;16:225–60.CrossRefPubMedGoogle Scholar
  18. 18.
    Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer. 2002;2:301–10.CrossRefPubMedGoogle Scholar
  19. 19.
    Karin M, Yamamoto Y, Wang QM. The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov. 2004;3:17–26.CrossRefPubMedGoogle Scholar
  20. 20.
    Puvvada SD, Funkhouser WK, Greene K, Deal A, Chu H, Baldwin AS, et al. NF-kB and Bcl-3 activation are prognostic in metastatic colorectal cancer. Oncology. 2010;78:181–8.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Biswas DK, Dai SC, Cruz A, Weiser B, Graner E, Pardee AB. The nuclear factor kappa B (NF-kappa B): a potential therapeutic target for estrogen receptor negative breast cancers. Proc Natl Acad Sci U S A. 2001;98:10386–91.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Sweeney C, Li L, Shanmugam R, Bhat-Nakshatri P, Jayaprakasan V, Baldridge LA, et al. Nuclear factor-kappaB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate. Clin Cancer Res: Off J Am Assoc Cancer Res. 2004;10:5501–7.CrossRefGoogle Scholar
  23. 23.
    Weichert W, Boehm M, Gekeler V, Bahra M, Langrehr J, Neuhaus P, et al. High expression of RelA/p65 is associated with activation of nuclear factor-kappaB-dependent signaling in pancreatic cancer and marks a patient population with poor prognosis. Br J Cancer. 2007;97:523–30.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Tang X, Liu D, Shishodia S, Ozburn N, Behrens C, Lee JJ, et al. Wistuba, II: nuclear factor-kappaB (NF-kappaB) is frequently expressed in lung cancer and preneoplastic lesions. Cancer. 2006;107:2637–46.CrossRefPubMedGoogle Scholar
  25. 25.
    Karin M. Nuclear factor-kappa B in cancer development and progression. Nature. 2006;441:431–6.CrossRefPubMedGoogle Scholar
  26. 26.
    Karin M, Greten FR. Nf-kappab: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005;5:749–59.CrossRefPubMedGoogle Scholar
  27. 27.
    Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature. 2004;431:461–6.CrossRefPubMedGoogle Scholar
  28. 28.
    Hoeppner CZ, Cheng N, Ye RD. Identification of a nuclear localization sequence in beta-arrestin-1 and its functional implications. J Biol Chem. 2012;287:8932–43.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Yang M, He RL, Benovic JL, Ye RD. Beta-arrestin1 interacts with the G-protein subunits beta(1)gamma(2) and promotes beta(1)gamma(2)-dependent Akt signalling for NF-kappa B activation. Biochem J. 2009;417:287–96.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Yang M, Zhang H, Voyno-Yasenetskaya T, Ye RD. Requirement of Gbetagamma and c-Src in D2 dopamine receptor-mediated nuclear factor-kappaB activation. Mol Pharmacol. 2003;64:447–55.CrossRefPubMedGoogle Scholar
  31. 31.
    Cianfrocca R, Tocci P, Semprucci E, Spinella F, Di Castro V, Bagnato A, Rosano L: Beta-arrestin 1 is required for endothelin-1-induced NF-kappaB activation in ovarian cancer cells. Life sciences 2014Google Scholar
  32. 32.
    Edge SB, Compton CC. The American joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471–4.CrossRefPubMedGoogle Scholar
  33. 33.
    Sobolesky PM, Moussa O. The role of beta-arrestins in cancer. Prog Mol Biol Transl Sci. 2013;118:395–411.CrossRefPubMedGoogle Scholar
  34. 34.
    Rosano L, Cianfrocca R, Tocci P, Spinella F, Di Castro V, Spadaro F, et al. Beta-arrestin-1 is a nuclear transcriptional regulator of endothelin-1-induced beta-catenin signaling. Oncogene. 2013;32:5066–77.CrossRefPubMedGoogle Scholar
  35. 35.
    Angileri FF, Aguennouz M, Conti A, La Torre D, Cardali S, Crupi R, et al. Nuclear factor-kappaB activation and differential expression of survivin and Bcl-2 in human grade 2-4 astrocytomas. Cancer. 2008;112:2258–66.CrossRefPubMedGoogle Scholar
  36. 36.
    Li D, Beisswenger C, Herr C, Schmid RM, Gallo RL, Han G, et al. Expression of the antimicrobial peptide cathelicidin in myeloid cells is required for lung tumor growth. Oncogene. 2014;33:2709–16.CrossRefPubMedGoogle Scholar
  37. 37.
    Stathopoulos GT, Sherrill TP, Han W, Sadikot RT, Yull FE, Blackwell TS, et al. Host nuclear factor-kappaB activation potentiates lung cancer metastasis. Mol Cancer Res: MCR. 2008;6:364–71.CrossRefPubMedGoogle Scholar
  38. 38.
    Nair VS, Gevaert O, Davidzon G, Plevritis SK, West R. Nf-kappaB protein expression associates with (18)F-FDG pet tumor uptake in non-small cell lung cancer: a radiogenomics validation study to understand tumor metabolism. Lung Cancer. 2014;83:189–96.CrossRefPubMedGoogle Scholar
  39. 39.
    Annunziata CM, Stavnes HT, Kleinberg L, Berner A, Hernandez LF, Birrer MJ, et al. Nuclear factor kappa B transcription factors are coexpressed and convey a poor outcome in ovarian cancer. Cancer. 2010;116:3276–84.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Yang S-H, Hsu C-H, Lee J-C, Tien Y-W, Kuo S-H, Cheng A-L. Nuclear expression of glioma-associated oncogene homo log 1 and nuclear factor-kappa B is associated with a poor prognosis of pancreatic cancer. Oncology. 2013;85:86–94.CrossRefPubMedGoogle Scholar
  41. 41.
    Hatata T, Higaki K, Tatebe S, Shomori K, Ikeguchi M. Immunohistochemical study of nuclear factor-kappaB expression in esophageal squamous cell carcinoma: prognostic significance and sensitivity to treatment with 5-fu. Dis Esophagus: Off J Int Soc Dis Esophagus ISDE. 2012;25:716–22.CrossRefGoogle Scholar
  42. 42.
    Yamanaka N, Sasaki N, Tasaki A, Nakashima H, Kubo M, Morisaki T, et al. Nuclear factor-kappaB p65 is a prognostic indicator in gastric carcinoma. Anticancer Res. 2004;24:1071–5.PubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Jianyu Yu
    • 1
    • 2
  • Liguang Wang
    • 3
  • Tiehong Zhang
    • 3
  • Hongchang Shen
    • 3
  • Wei Dong
    • 1
  • Yang Ni
    • 3
  • Jiajun Du
    • 1
    • 3
  1. 1.Department of Thoracic Surgery, Shandong Provincial Hospital Affiliated to Shandong UniversityShandong UniversityJinanPeople’s Republic of China
  2. 2.Department of General SurgeryChinese People’s Liberation Army (PLA) 230th HospitalDandongPeople’s Republic of China
  3. 3.Institute of Oncology, Shandong Provincial Hospital Affiliated to Shandong UniversityShandong UniversityJinanPeople’s Republic of China

Personalised recommendations